Cargando…

Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response

BACKGROUND: The oncogenic PI3K/Akt/mTOR pathway is frequently activated in HCC. Data on the mTOR inhibitor, temsirolimus, is limited in HCC patients with concomitant chronic liver disease. The objectives of this study were: (1) In phase I, to determine DLTs and MTD of temsirolimus in HCC patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeo, Winnie, Chan, Stephen L, Mo, Frankie KF, Chu, Cheuk M, Hui, Joyce WY, Tong, Joanne HM, Chan, Anthony WH, Koh, Jane, Hui, Edwin P, Loong, Herbert, Lee, Kirsty, Li, Leung, Ma, Brigette, To, Ka F, Yu, Simon CH
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4434865/ https://www.ncbi.nlm.nih.gov/pubmed/25962426 http://dx.doi.org/10.1186/s12885-015-1334-6

Ejemplares similares

Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma – clinical application of health-related quality-of-life data
por: Li, Leung, et al.
Publicado: (2017)

Quality of life of young Chinese breast cancer patients after adjuvant chemotherapy
por: Yeo, Winnie, et al.
Publicado: (2018)

Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus
por: Boni, J P, et al.
Publicado: (2008)

Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model
por: Chang, Hsuen-Wen, et al.
Publicado: (2018)

Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies
por: Yeo, Winnie, et al.
Publicado: (2021)

The association of liver function and quality of life of patients with liver cancer
por: Li, Leung, et al.
Publicado: (2019)

NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin
por: Yeo, Winnie, et al.
Publicado: (2022)

Quality of Life Associated with Nausea and Vomiting from Anthracycline‐Based Chemotherapy: A Pooled Data Analysis from Three Prospective Trials
por: Yeo, Winnie, et al.
Publicado: (2021)

Evaluating the activity of temsirolimus in neuroendocrine cancer
por: O'Donnell, P H, et al.
Publicado: (2007)

Prospective evaluation of plasma Epstein–Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma
por: Ma, Brigette, et al.
Publicado: (2018)

Characterization of rare transforming KRAS mutations in sporadic colorectal cancer
por: Tong, Joanna HM, et al.
Publicado: (2014)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

Dataset on chemotherapy-induced nausea and vomiting (CINV) and quality of life (QOL) during multiple chemotherapy cycles among a Chinese breast cancer patient population who were randomized to antiemetic regimens with or without olanzapine
por: Yeo, Winnie, et al.
Publicado: (2020)

Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mIBI in patients with hepatocellular carcinoma
por: Li, Leung, et al.
Publicado: (2019)

Reply: Evaluating the activity of temsirolimus in neuroendocrine cancer
por: Duran, I, et al.
Publicado: (2007)

Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients
por: Boyle, H., et al.
Publicado: (2011)

A pilot study of temsirolimus and body composition
por: Veasey-Rodrigues, Heloisa, et al.
Publicado: (2013)

Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study
por: Salem, Riad, et al.
Publicado: (2021)

Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
por: Luo, Laihui, et al.
Publicado: (2022)

Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma
por: Chan, Stephen L, et al.
Publicado: (2006)

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
por: Samad, Nousheen, et al.
Publicado: (2010)

Profile of temsirolimus in the treatment of advanced renal cell carcinoma
por: Staehler, Michael, et al.
Publicado: (2010)

Renal Cell Carcinoma: Focus on Safety and Efficacy of Temsirolimus
por: Hadoux, Julien, et al.
Publicado: (2010)

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
por: Galimberti, S, et al.
Publicado: (2010)

Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma
por: Venugopal, Balaji, et al.
Publicado: (2013)

Stereotactic Percutaneous Electrochemotherapy as Primary Approach for Unresectable Large HCC at the Hepatic Hilum
por: Luerken, L., et al.
Publicado: (2021)

Knowledge, Attitudes and Practices Towards COVID-19 Amongst Ethnic Minorities in Hong Kong
por: Wong, Cho Lee, et al.
Publicado: (2020)

Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center
por: Afshar, Mehran, et al.
Publicado: (2014)

Comparing the long-term efficacy of standard and combined minimally invasive procedures for unresectable HCC: a mixed treatment comparison
por: Zhao, Jianghai, et al.
Publicado: (2016)

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?
por: Kirschey, Sebastian, et al.
Publicado: (2012)

Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype
por: Gabriel, Diana, et al.
Publicado: (2016)

Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma
por: Kaley, Thomas J., et al.
Publicado: (2020)

Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC
por: Li, Ting, et al.
Publicado: (2023)

Reconstitution of bone-like matrix in osteogenically differentiated mesenchymal stem cell–collagen constructs: A three-dimensional in vitro model to study hematopoietic stem cell niche
por: Lai, WY, et al.
Publicado: (2013)

Update in Antiepidermal Growth Factor Receptor Therapy in the Management of Metastatic Colorectal Cancer
por: Loong, Herbert H., et al.
Publicado: (2009)

Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study
por: Sugiyama, Shigeru, et al.
Publicado: (2020)

Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma
por: Wang, Li, et al.
Publicado: (2010)

A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma
por: Verschraegen, Claire F., et al.
Publicado: (2013)

Activation of the unfolded protein response in sarcoma cells treated with rapamycin or temsirolimus
por: Briggs, Joseph W., et al.
Publicado: (2017)

Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
por: Lee, Jii Bum, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hqod28ilgb91sr1uoidhq18kth